Unlike conventional production systems where purification and impurity removal, or polishing, are carried out seperately the ‘Kremer Method’ combines these operations into a single-step using in-line dilution.
This approach elimnates to need to store material during production and reduces the amount of buffers and resins that are required and, according to DSM, cuts preparation times and labour requirements.
The Netherland’s based contract manufacturing organisation (CMO) firm said that the new method is can achieve 90 per cent product recovery rates and host cell protein (HCP) was removed to below the limit of detection.
The Kremer Method extends DSM’s biomanufacturing offer, which includes XD, a system that boosts cell densities in production vessles, and Robust, an expanded bed chromatography system that uses cross linked agarose beads with Tungsten Carbide to increase the particle density during downstream processing.
This expansion was highlighted by DSM Biologics president Karen King, who suggested that combining the Kremer Method with the firm’s other technologies will cut “overall costs and processing times of biopharmaceuticals while maintaining high product quality."
This was echoed by Rolf Douwenga, VP of global R&D for DSM Biologics, who described the Kremer Method as a “valuable addition to the platform of DSM's technologies addressing the full range of mammalian cell culture systems for protein and monoclonal antibody production.
DSM’s efforts to extend its biomanufacturing offering is unsurprising given that, in April, it attributed a 14 per cent drop in revenues generated by its pharmaceutical business to drug companies are either focusing on ‘niche’ high value drugs and biopharmaceuticals or on high volume products for emerging markets.